Robert W. Baird analyst Brian Skorney maintained a Buy rating on Myovant Sciences (NYSE:MYOV) on Friday, setting a price target of $30, which is approximately 22.90% above the present share price of $24.41.
Skorney expects Myovant Sciences to post earnings per share (EPS) of -$0.89 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Myovant Sciences, with an average price target of $35.25.
The analysts price targets range from a high of $55 to a low of $24.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $24.61 million and a net profit of -$76.95 million. The company's market cap is $2.23 billion.
According to TipRanks.com, Robert W. Baird analyst Brian Skorney is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 5.0% and a 51.69% success rate.
Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.